Karyopharm Therapeutics(US:KPTI) Prnewswire·2025-10-08 11:00Core Insights - Karyopharm Therapeutics has secured $100 million in financing to enhance financial flexibility and extend its cash runway into Q2 2026, supporting ongoing clinical trials and operations [1][5][10] - Preliminary total revenue for Q3 2025 is expected to be between $42 million and $44 million, with U.S. XPOVIO net product revenue projected at approximately $32 million [6][7] - The company is on track to report top-line data from the Phase 3 SENTRY trial in myelofibrosis by March 2026 [1][9] Financing Transactions - The financing includes a private placement of 1,487,917 shares of common stock and warrants to purchase 1,317,771 shares at an exercise price of $6.64, expected to generate approximately $8.75 million in gross proceeds [2][3] - The company will issue a total of 7,223,982 new shares and various warrants, with a reduction in the exercise price of existing warrants from $16.50 to $6.64 [3][5] - The financing aims to comply with Nasdaq rules and is structured to strengthen the balance sheet and equitize near-term debt maturities [1][3] Clinical Trials and Programs - The Phase 3 SENTRY trial is evaluating selinexor in combination with ruxolitinib for myelofibrosis, with co-primary endpoints focused on spleen volume reduction and symptom score improvement [13] - Enrollment is ongoing in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with top-line data expected in mid-2026 [9][17] - Karyopharm's lead compound, selinexor, is positioned as a potential first combination therapy for myelofibrosis, aiming to redefine treatment standards [1][15] Financial Position - Prior to the financing, Karyopharm reported approximately $46 million in cash and equivalents as of September 30, 2025 [7][8] - The financing transactions are expected to provide significant financial flexibility, including $67.5 million in new capital and deferrals of interest and royalty payments [5][10]